Regenerative medicine inquiry

Inquiry Regenerative medicine inquiry

Witnesses Dr Nick Crabb, Programme Director, Scientific Affairs, National Institute for Health and Care Excellence, Dr Jonathan Fielden, Director of Specialised Commissioning and Deputy National Medical Director, NHS England, and Dr James Palmer, Clinical Director of Specialised Commissioning, NHS England; Professor Amit Nathwani, Professor of Haematology, Royal Free Hospital, Professor Giovanna Lombardi, Professor of Human Transplant Immunology, King’s College London, and Dr Anthony Mathur, Professor of Cardiology, Queen Mary’s School of Medicine and Dentistry; Lord Prior of Brampton, Parliamentary Under-Secretary of State for Health, Department of Health

Witnesses Dr Ian Hudson, Chief Executive, Medicines and Healthcare Products Regulatory Agency, Professor Paul Whiting, Member, Medical Research Council Regenerative Medicine Research Committee, Dr Sven Kili, Head of Gene Therapy Development, GlaxoSmithKline, and Michael Hunt, Chief Financial Officer, ReNeuron Group; Ian Trenholm, Chief Executive, NHS Blood and Transplant, Ian McCubbin, Medicines Manufacturing Industry Partnership and co-chair of the Advanced Therapy Manufacturing Taskforce, Keith Thompson, Chief Executive Officer, Cell and Gene Therapy Catapult, and Dr Ruth McKernan, Chief Executive, Innovate UK

Witnesses Professor Paul Riley, British Heart Foundation Professor of Regenerative Medicine, University of Oxford, Professor Stuart Forbes, Professor of Transplantation and Regenerative Medicine, University of Edinburgh, Professor Peter Andrews, Professor of Biomedical Science, University of SheffieldDr Rob Buckle, Director of UK Regenerative Medicine Platform, Research Councils UK, Professor Jeremy Pearson, Associate Medical Director, British Heart Foundation, Professor Neil Hanley, Professor of Medicine, University of Manchester, Professor Anthony Hollander, Head of Institute of Integrative Biology and Professor of Stem Cell Biology, University of Liverpool